Register for #ASGCTBreakthroughs24 to learn about the latest advancements in CGT for muscular dystrophy! Join us Nov. 19-20 in Chicago or virtually.
In Q4, FDA approved U.S.-first gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease.
The second quarterly report of 2023 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
The first quarterly report of 2023 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
The Gene, Cell, & RNA Therapy Landscape report from ASGCT and Citeline (formerly Informa Pharma Intelligence) is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
November 19-20, 2024 | Chicago, IL
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico